Accessibility settings

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/59274, first published .
Man wearing a face mask looks out a window during quarantine.

Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study

Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study

Journals

  1. Okushin K, Ikeuchi K, Saito M, Kishida T, Kado A, Fujishiro M, Moriya K, Yotsuyanagi H, Koike K, Tsutsumi T. Use of Ursodeoxycholic Acid and the Risk of Severe Coronavirus Disease 2019 in Elderly Patients with Viral Hepatitis. Internal Medicine 2025;64(15):2301 View
  2. Park S, Moon E. Ursodeoxycholic Acid Attenuates B Cell Susceptibility to SARS-CoV-2 Spike Protein by Interfering Its Binding to ACE2. Biomolecules & Therapeutics 2025;33(6):1064 View
  3. Song J, Shim S, Shin J, Choe W, Park J, Lee T, Kang S, Rhee T, Huh K. Clinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose–response meta-analysis. Frontiers in Pharmacology 2026;17 View
  4. Tong Z, Zhu J, Zhong J, Wang Q, Qian F, Zhao L, Wang W, Cai Y, Qin K. Ursodeoxycholic Acid Reduces Angiotensin‐Converting Enzyme 2 Activity and Suppresses Cytokine Storm Syndrome in Patients With Coronavirus Disease 2019. MedComm 2026;7(9) View
  5. Wan J, Zong H, He D, Li D, Yu J, Wang G, Liu L, Huang C, Wang X, Wang L. Bile Acids and Their Receptors in Respiratory Diseases: Mechanistic and Therapeutic Perspectives. Biomolecules 2026;16(10):1497 View